Flying High: China’s Eddingpharm Takes Another Step With Its First Global Licensing Deal
This article was originally published in PharmAsia News
In its latest deal, Eddingpharm continues its march forward from a third-party promotional partner for companies like GSK, to a China-based specialty pharma. After in-licensing a string of compounds last year, it has now added three more from ACT Biotech.
You may also be interested in...
Oncology focused startup EOC Pharma expects to develop an “exciting” pipeline in two years via the licensing model. The company is also seeking “constant” financing as it advances three drug candidates into the next stage in 2018, EOC CEO Xiaoming Zou tells Scrip in an interview.
While many pharma firms in China choose to partner with US companies, Jiangsu Hengrui is relying on itself to go global. The Chinese pharma giant is betting on its newly established US subsidiary Luzsana in a major move to make its wide-ranging products more available, accessible and affordable to patients in the US and the rest of the world.
Home-grown Chinese mRNA COVID-19 vaccines are more effective than domestic inactivated virus-based shots, new trial results show.